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objectives), two separate manuscripts, a general conclusion, references and 
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Pseudorabies is an acute, infectious and often fatal disease occurring 
in many domestic animals of economic importance. The disease, caused 
by a herpesvirus, is prevalent in many countries throughout the world, including 
North, South· and Central Americas, Africa, Europe, Russia and China. Literature 
reports deal primarily with the disease incidence in Europe and North America, 
where swine, cattle, sheep and goats, among others, may be affected (4). 
Primary economic losses occur in both swine and cattle industri~s, but the 
severest losses are met in swine breeding. The disease in swine causes a 
host of reproductive pr.oblems, including abortion, production of mummified 
fetuses, stillbirth and death in neonatal pigs. 1 Pseudorabies is generally 
milder in older pigs, but recent trends toward increased mortality in adult 
animals suggest that more ·virulent strains of virus are present in the hog 
population (17 ,37). Swine serve as the only known reservoir for the virus, 
and carrier ·animals contribute to disease spread to penmates as well as to 
other domestic animals (14). Pseudorabies in cattle is almost.invariably 
fatal, causing intense pruritis and neurologic damage before death·(l4}. 
The endemic nature of the disease in Europe2 and its increased incidence 
and severity in the United States (17 ,37) has heightened concern for economic 
1Econohlic Analysis of Pseudorabies Program Options report made 
availabl.e by USDA-A PHIS at the National Pseudorabies Hearing, St. 
Louis, May, 1981. 
2control of Aujeszky's Disease in Europe by Vaccination, presented 
by Norden Laboratories (Lincoln, Nebraska) at the National State Veterinary 
Meeting, ·Lincoln, May 1978. 
2 
losses and encouraged the development of vaccines to control losses. 
Available Vaccines 
Many pseudorabies vaccines are presently available for commercial 
use. In. European countries, vaccines of the modified live type have been 
in use since the 1960s. The Bucharest virus strain, that was ·adapted to grow 
in the chorioallantoic membrane (CAM) of eggs, has been the source of several 
vaccines. Bran et al. (5) developed a vaccine by emulsifying Bucharest strain 
infected CAMs with aluminum hydroxide. This vaccine has been widely used 
in Rumania. In Czechoslovakia, Zuffa and Polak (51) developed the BUK 
vaccine by passing the Bucharest strain in chick embryo fibroblast (CEF) 
~ 
cell cultures, until it had lost virulence for calves and pigs. Skoda et al. 
(34) attenuated the Bucharest strain by extensive passage in CAMs and in 
CEF cell cultures, developing the TK200 vaccine. In Hungary, Bartha and 
Kojnok (3) developed the K strain vaccine, using a virus strain isolated from 
a clinical pseudorabies outbreak in pigs. The K strain, which was nonvirulent 
for pigs, was chosen for its atypical cytopathic effect on pig kidney monolayers 
at 32°C (2). Toneva (39) developed an attenuated vaccine by blind passage 
of pseudorabies virus in pigeon brains. 
Only one modified Jive vaccine has been federally licensed in the United 
States. In 1977, Norden Laboratories (Lincoln, Nebraska) (37) developed 
this vaccine from the BUK vaccine strain, which they adapted to grow on 
a porcine kidney cell line. 
Many inactivated pseudorabies vaccines were developed in Europe 
during ttie 1960s. The most effective of these vaccines for swine were inactivated 
3 
with formaldehyde or glutaraldehyde, and mixed with oil adjuvant (8,38). 
The availability of pseudorabies inactivated vaccines in the Unite.d 
States has been more recent. In 1978, Salsbury Laboratories (Charles City, 
Iowa) (17) was the first to develop a killed vaccine that was prepared from 
virus propagated in primary porcine tissue culture. The virus was chemieally 
inactivated and mixed with adjuvant. Norden Laboratories developed an 
adjuvant-emulsified, inactivated vaccine 1 that was federally licensed in 
1980. 
Pseudorabies vaccines in the United States have been only recently 
available for commercial use, allowing insufficient time for a fair evaluation 
of field performance. Mo.st of the European vaccines, however, have been 
in use for many years, permitting some conclusions to be drawn concerning 
their safety, efficacy and role in disease eradication. 
Modified live vaccines are generally preferred because small doses 
of virus will .induce a higher level and longer lasting immunity than killed 
vaccines (12). Multiplication of the vaccine strain creates high levels of 
antigen without producing a typical disease. 2 The greatest problem with 
attenuated vaccines is one of safety. Incomplete attenuation of the vaccine 
strain has, in some cases; resulted in vaccine-induced temperature responses, 
clinical signs, abortions, disease in neonatal pigs and shedding of vaccine 
virus (4,37). Excretion of vaccine virus causes inadvertent immunization 
1 Info~mation from vaccine product insert, PR-Vac, Norden Laboratories, 
Lincoln Nebraska. 
2control of Aujeszky's Disease by Vaccination, presented by Norden 
Laboratories (Lincoln, Nebraska) at the National State Veterinary Meeting, 
Lincoln, May 1978. · 
4 
of in-contact swine. This would permit possible reversion to virulence by 
repeated passage through hosts (4). While vaccine virus may be quite safe 
in pigs, it may be insufficiently attenuated to prevent infection and disease 
in other species (37). Live herpesvirus vaccines also are potential vehicles 
for transfection (16) and establishing oncogenic and persistent infections 
(12,48). 
Safety is the primary reason for using inactivated vaccines. In general, 
however, they have not been very successful in the field. They are expensive 
and difficult to prepare with sufficient antigen and lack effectiveness in 
stimulating local immunity (4,37). Because oncogenic potential persists 
in killed herpesvirus preparations (30), vaccine-induced transformation of 
normal host cells is possible. 
Ba.th types of pseudorabies vaccines have reduced economic loss and 
clinical .symptoms. However, they do not necessarily prevent super infection 
with virulent virus, permitting its subsequent excretion and persistence on 
an infected farm (4,28). Hogs that have been vaccinated with attenuated 
or killed products are indistinguishable serologically from infected animals. 1 
Presently available vaccines are thus not compatible with eradication programs.2 
1 
Economic Analysis of Pseudorabies Program Options, report made 
available by USDA-APHIS at the National Pseudorabies Hearing, St. 
Louis, May 1981. 
2Con~rol of Aujeszky's Disease in Europe by Vaccination, presented 
by Norden Laboratories (Lincoln, Nebraska) at the National State Veterinary 






Subunit vaccines, containing only those viral structural components 
required for evoking a protective immune response, have been reviewed 
by Rubin and Tint (33) and Reed (31). Preparatory procedures may contribute 
to the safety of the vaccine by eliminating whole virus, viral nucleic acid, 
immunosuppressive fractions, pyrogens and allergenic components (31,33). 
The removal of nucleic acids precludes the establishment of latent infections 
and oncogenesis in the vacc inate (31,33). Large doses of immunogen from 
fully virulent virus also may be administered without adverse effects (31). 
The efficacy of subunit vaccines has been confirmed by recent work with 
infectious bovine rhinotracheitis virus (21) and pseudorabies virus (32) infected 
cell extrac ts. Because the vaccine contains only a portion of the virus, serologic 
tests easily may be designed to distinguish vaccinates from infected animals, 
thus making their use compatible with eradication programs (31). 
Viral subunit components may require the addition of adjuvant for 
immunogenicity. If they are of low molecular weight, aggregation or carrier 
coupling may also be necessary (31 ). Present subunit extraction procedures 
are expensive, making the vaccines cost ly to produce (31). Mass production 
of these vaccines may become more economical when additional progress 
is made in the areas of synthetic vaccine technology, involving chemical 
synthesis of immunologically active viral antigenic determinants (1), and 
recombinant DNA (deoxyribonucleic acid) technology, involving the deveiopment 
of microbial factories to produce the viral immunogen in sufficient quantities 
(9). 
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Herpes Split Vaccines 
A variety of viral subunit vacci,nes has been used experimentally with 
some success. Herpes subunit vaccines include those for herpes simplex 
virus type l (HSV-1), (6,29,35), pseudorabies virus (PR V) (32), infectious bovine 
rhinotracheitis virus (IBRV) (2i), equine herpesvirus type 1 (EHV-1) (26) and 
Marek's disease virus (MDV) (18,49). Most of these herpesvirus vaccines 
are not true subunit vaccines, but are crude extracts of virus-specific host 
cell proteins rather than purified subunits. These, therefore, will be referred 
to as "split" vaccines. 
Cappel et al. (6) solubilized HSV-1 envelope proteins with the nonionic 
detergent, Nonidet P-40 (NP40). The solubilized material was mixed with 
adjuvant and used to immunize rabbits. Twice-vaccinated rabbits developed 
both humoral'and cell-mediated immunity and demonstrated an 80% protection 
rate against lethal challenge. Raj~ani et al. (29) prepared a vaccine by NP-
40 solubilization of HSV-1 infected cells. The solubilized extract was mixed 
with Freund's incomplete adjuvant and was administered in 3 doses to rabbits;· 
Immunized rabbits were challenged by HSV-1 infection of scarified corneas 
and were later sacrificed to examine trigeminal ganglia. Vaccinates were 
found to have .a reduced number of virus-carrier ganglion cells when compared 
to controls. Slichtov~ et al. (35) also used NP-40 to solubilize HSV-1 infected 
·cells. Mice were vaccinated subcutaneously with a single dose of this adjuvanted 
vaccine. After. intradermal challenge, vaccinates and controls were observed 
for skin lesion development and neurological symptoms. Vaccinates were 
fully protected from viral encephalitis and the severity of their lesions were 
limited. Immunization also appeared to result in the accelerated clearance 
7 
of virus. 
Rock and Reed (32) prepared an experimental split vaccine from nonionic 
detergent extracts of PR V infected cells. The solubilized antigens, free 
of inf_ectious virus, were mixed with Freund's incomplete adjuvant and 1..1sed 
to vaccinate mice. Vaccinates produced both a cellular immune response 
and neutralizing antibody. Twice-vaccinated mice were protected from 
challenge and demonstrated neutralizing antibody titers of approximately 
1:4,000. 
An experimental, detergent•split IBRV vaccine was prepared with NP.,. 
40 (21). The adjuvanted· vaccine, administered to calves in two doses, produced 
high serum neutralizing titers and prevented clinical disease. In addition, 
calves were tnought not to be infected by challenge virus and did.not shed 
v!rus after challenge. 
_An EHV-1 vaccine was prepared by treating purified virus preparations 
- .. 
with the .detergent Rexol 2.5J and mixing the envelope extracts with Freund's 
adjuvant (26). Hamsters receiving two doses of the vaccine were protected 
against challenge. 
Two adjuvant-~mulsified, detergent split vaccines against MDV were 
investigated. Separate vaccines were prepared from MDV (18) and turkey 
herpesvirus infected cells (49). The MDV vaccine protected the rllaj?rity 
of vaccinated chickens from disease. Turkey herpesvirus detergent extracts 
were passed through a concanavalin A (con A) Sepharose column to separate 
out glycoproteifis. The eluted glycoprotein fraction was purified further 
by sodium dodecylsulphate-polyacrylamlde gel electrophoresis (SDS-PAGE) 
. . 
and found to: contain 3 viral glycopeptides. These glycopeptides were cut 
8 
· fro1!1 the gel, pooled, mixed with Freund's incomplete adjuvant, and administered 
to chickens. Vaccinates forn;ied neutralizing antibodies but only partial protection 
resulted from challenge with virulent Marek's disease virus. Incomplete 
protection may have been due to SOS denaturation of immunizing proteins 
(49). 
Protective Antigens 
Herpesviruses basically are composed of a nucleocapsid and an envelope. 
The immunogenic properties of nucleocapsid .and envelope antigens have 
been investigated and compared (13,22,26,27). The envelope proteins, specifically 
the glycoproteins, are the major targets of neutralizing antibodies and therefore 
play an important protective role in the infected host (6,!3,19,22,26,27,50). 
Rabbits inoculated with HSV-1 envelope preparations developed high titers 
of neutralizing antibodies (19) and a cellular immune response (6). Immunization 
with HSV-1 envelope preparations induced higher neutralizing antibody titers 
in humans and rabbits than did nucleocapsid (13,22), and protected rabbits 
from lethal challenge (50). Similar differences in titers were found with 
equine herpesvirus type-I (EHV-1) envelope and nucleocapsid preparations 
in hamsters (27); lethal challenge of hamsters vaccinated with nucleocapsid 
or envelope antigens resulted in protection of envelope vaccinates only (26). 
Identification of Glycosylated Antigens 
Studies .by Kaplan (15) and Vestergaard (44) revealed that only a small 
fraction (total numbers and quantities) of herpesvirus envelope antigens 
becornes virion incorporated, while the majority remains associated with 
9 
the host cell membrane. Infected host cells have served as an excellent 
source of viral antigens for analytical work with SDS-PAGE and crossed 
immunoelectrophoresis (CIE) (25). Because herpes simplex antigens have 
been analyzed extensively with little information being available on other 
herpesviruses, discussion will be restricted to HSV-1. 
Sodium dodecylsulphate~polyacry!amide gel e!ectrophoretic analysis 
of 14C-glucosamine or 14c-amino acids labelled HSV-1 specific infected 
cell membrane antigens revealed 12 polypeptides, 9 of which were glycosylated. 
The membrane glycoproteins 7, 8 and 18 were found to be electrophoretically 
similar to the HSV-1 virion proteins (VPs) 7, 8 and 18, respectively (10). 
The SDS-PAGE analysis denatures proteins and causes an alteration 
of their biological conformation an.d immunological activity (7). Nonionic 
detergents, such as Triton X-100,_extract whole membrane proteins from 
infected cells by binding to th.e hydrophobic domain of intrinsic membrane 
proteins. Detergent replacement of the lipid environment results in the 
solubilizatior\ of protein in its native conformation (11). 
Crossed immunoelectrophoresis of Triton X-100 solubilized infected 
cell extracts, followed by protein staining, consistently separated three distinct 
HSV-1 antigens - Ags 6, 8 and 11 (20,24,40,42,43,46,47). In separate experiments, 
crossed immunoaffinoelectrophoresis (con A Sepharose incorporated into 
an intermediate gel) and_ 1,tiC-glucosamine labelling of infected cell antigens 
identified all three antigens as glycoproteins (23,ti!,l/3). Antisera'.individually 
prepared against Ags 6, 8 and 11, neutralized HSY-I virus particles, indicating 
that these same or antigenically similar antigens were present on the virion 
envelope (titi). Crossed immunoelectrophoresis of Ilic-protein hydrolysate 
10 
labelled infected· cell extracts, followed by autoradiography, revealed four 
additional antigens, Ags 3, 3A, 6A and 7 (20,23,24,43,45,47), the glycosylation 
statuses of which have not been confirmed. 
Biological Function of Glycosylated Antigens 
The major HSV-1 glycoprotein antigens and their functional roles have 
been reviewed by Norrild .(25) and Spear et al. (36). Glycoproteins gA, gB, 
gC, gD and gE (designated by the Workshop on Herpesviruses, Cambridge, 
England, 1978) are pr.esent in both the virion and plasma membrane of virus 
infected cells. The functions of each are as follows: gA--unknown, gB--required 
for infectivity, gC--suppression of poly!<aryocyte formation, gD~-unknown 
and gE--Fc receptor. Crossed immunoelectrophoresis separated HSV-1 Ags 
6, 8 and 11 correspond serologically to gC, gD and gA + gB, respectively~ 
The SOS-PAGE separated virion proteins, VPs 7, 8, 8.5 and 18 correspond 
to gB, gC, gA and gD, respectively. 
Objectives 
The objectives in this study were to characterize pseudorabies virus 
specific antigens present in infected cell membrane extracts. Antigens were 
enumerated and characterized by glycosylation and protective activity. 
PART I. 
11 
CROSSED IMMUNOELECTROPHORETIC CHARACTERIZATION 
OF PSEUDORABIES (AUJESZKY'S DISEASE) VIRUS ANTIGENS 
This manuscript has been submitted for publication to th.e Archives of Virology. 
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From the Veterinary Medical Research Institute, Iowa State University, 
Ames, Iowa 50011 
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SUMMARY 
Detergent solubilized antigens from pseudorabies virus (PR V) infected 
cells were characterized by crossed immunoelectrophoresis. Patterns revealed 
16 virus-specific antigens, 13 of which were glycosylated. 
14 
INTRODUCTION 
Sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
is used frequently in the analysis of herpesvirus infected cell antigens (2,3,5,7 ,-
8,13). The ionic detergent, SDS, denatures proteins causing a marked reduction 
in immunological function (22,27). Nonionic detergents, such as Triton X~ 
100, are used to solubilize membrane bound proteins without altering their 
immunological activity (4,28). Herpesvirus-specific membrane antigens 
have been solubilized by Triton X-100 (7,10,ll,13,14,18,l9,20,21,22,23,24,25,26) 
and analyzed by crossed immunoelectrophoresis (CIE) (10,19,20,21,22,23,24,25,26). 
The purpose of the present study was to characterize Triton X-100 solubilized 
pseudorabies (Aujeszky's disease) virus antigens by CIE. 
15 
MATERIALS AND METHODS 
Cell Culture 
Bovine lung (BL) cel~s were grown in monolayers in Eagle's minimum 
essential medium with Earle's salts (MEM) supplemented with 10% fetal 
bovine serum, 0.1% lactalbumin hydrolysate, 0.16% sodium bicarbonate, 
8.3 mM N-2~hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) and 
antibiotics "(100 I.U. penicillin, JOO .ug streptomycin sulfate, 100 .ug kanamycin 
sulfate and 50 og gentamicin sulfate per ml). Cells were grown in closed 
" . " 0 
systems, on a roller apparatus, at 37 C. 
Virus 
Plaque-purified PRY strain S62/26 (17) was obtained from D. L. Rock 
(Vete~inary Medical Research Institute,.Jowa State University, Ames, Iowa). 
The virus was passed once in BL cells and a stock pool, containing 7 .7 x 108 
plaque forming units (PFU) per ml, was frozen at -70°C. 
Reference Antibody 
Goat .anti-PR V serum was provided by W. A. Hagemoser (Department 
of Veterinary Pathology, Iowa State University, Ames, Iowa). The goat was 
initially vaccinated intramuscularly with a modified live PRV vaccine (Norden 
Laboratories, Lincoln, Nebraska), followed by I/ monthly booster inoculations 
with crude f'RV antigen extracts (see Antigen Preparation section). Antibodies 
were prepared by precipitation with 1.85 M ammonium sulfate, and were 
dialyzed for 3 days (6 buffer changes) against O.O 1 M Phosphate .Buffer (PB) 
16 
(pH 7 .5). The antibodies were mixed with equal volun:ies of vacuum filtered 
DEAE Sephadex A-50 (Pharmacia Fine Chemicals, Piscataway, New Jersey) 
(preswollen in the same buffer), and allowed to adsorb for 2 hours with periodic 
stirring. Immunoglobulins were removed by vacuum filtration. The gel was 
resuspended in an equal vo.lume of 0.05M PB (pH 7.2), stirred, and vacuum 
filtered. Antibody containing filtrates were pooled, concentrated to half· 
the original serum volume' with polyethylene glycol 6,000 (Fisher Scientific 
Company, Fairlawn, New Jersey), and dialyzed for 3 days (6 buffer changes) 
against 0.025 M Tris-Tricine buffer (Biorad Laboratories, Richmond, California) 
containing I% (v/v) Triton X-100 (Sigma Chemical Company, St. Louis, Missburi) 
(TTT buffer, pH 8.6). 
Antigen Preparation 
Bovine lung cells were grown in 850 cm2 plastic roller bottles. Monolayers· 
were infected at a multiplicity of 5 PFU/cell and virus inoculum was adsorbed 
at 37°C for 90 minutes in MEM containing 5% fetal bovine serum. Residual 
inoculum was then removed, replaced with serum-free MEM, and infected 
cells were incubated at 37°C for 24 hours. Infected cells at 100% cytopathic 
effect, were scraped into· the medium and centrifuged in an angle he<;1d at 
W0,000 X g at 4°C for I hour. The pellet was resuspended in TTT buffer 
(pH 8.6) at a :volume of 2 mis per roller bottle. The suspension was sonicated 
(Braunsonic 1510) at 100 watts for three 20-second bursts, stirred for I hour·. 
at 4°C and centrifuged in an angle head at 100,000 X g for I hour at 4°C; 
The supernatant fluid (approximate protein content of 5 mg/ml) was collected, 
designated crude antigen extract (CA) and stored at 4°c. Crude antigen 
17 
control was prepared from uninfected BL cells in an identical manner. 
Radiolabelled antigens were similarly prepared with 3tt-glucosamine 
(11 Ci/mMol) or 3tt-leucine (1 Ci/mMol), which were used at a concentration 
of 10 .uCi/ml. Isotopes were added to infected cell cultures 3 hours after 
virus adsorption, and the labelling period lasted 21 hours. Uninfected cells 
were radiolabelled and served as controls. All labelled preparations were 
concentrated to one third their original volume. with polyethylene glycol 
20,000 (Fisher), Isotopes were ·purchased from Research Products International 
Corporation, Mount Prospect, Illinois. 
Crossed Immunoelectrophoresis 
Th_e procedures for crossed immunoelectrophoresis "(CIE) were essentially 
. . . 
the same as those used by Vestergaard (19). Electrophoresis was performed 
on 84 x 94 mm plastic plates (LKB, Rockville, Maryland) in 1.4 mm thick, 
1 % (w/v) agarose gel (Biorad). The agarose was dissolved in TTT buffer (pH 
8.6) containing 1 % polyethylene glycol 6,000, and TTT buffer (pH 8.6) was . 
present in electrophoresis chambers. First dimension electrophoresis was 
performed on 15 .ul of CA by applying 10 volts per cm for 90 minutes at 10°c. 
In the second dimension, the separated antigens were electrophoresed against 
agarose containing 15 or 20% reference antibody by applying 1.5 volts per 
cm for 18 to 24 hours at 10°c. Co-electrophoresis of two extract preparations 
was performed in the same manner. Coomassie brilliant blue R250 stain 
. ' 
(CBB) (Biorad) was used to visualize precipitates. Autoradiography. was performed 
by placing Ultrofilm 3tt (LKB) on the gel side of dried, stained CIE plates. 
The film was developed after 30 days exposure. 
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RESULTS 
The CBB pattern for unlabelled CA precipitates is given in Figure J. 
The CBB and autoradiogram results for 3tt-Jeucine CA alone and co-electrophoresed 
with unlabelled CA, are shown in Figure 2. Figure 3 gives the CBB and autoradiogram 
patterns for 3tt-glucosamine CA alone and co-elei:::trophoresed with unlabelled 
CA. A composite illustration of all precipitates detected by CIE is given 
in Figure 4. The patterns revealed 16 virus-specific antigens, 13 of which 
were glycosylated. With some exceptions, antigens were numbered by their 
relative anodic migration in the first dimension. Antigens in different patterns 
were identified by a combination of peak shape, height, intensity of staining 
and relative anodic migration in the first dimension. 
Antigens (Ags) 5;6,7 and 8 were better separated in the co-electrophoresis 
patterns than in conventional CIE patterns. Where it was difficult to identify. 
these antigens individually, the collection of peaks in that area was designated 
the 5,6,7 ,8 complex. 
One host-specific precipitate was detec~ed in autoradiograms of labelled 
cell controls (not shown), but it did not appear to correspond to any of the 
virus-specific antigens. The FBS peak was absent in autoradiograms, and 
co-electrophoresis of unlabelled CA with fetal calf serum increased the 
height of the FBS peak only (not shown). 
Figure 1. 
Figure 2. 
Coomassie brilliant blue stain of unlabelled CA (crude antigen) 
CIE pattern. 
3H-leucine CA (crude antigen) CIE patterns. (A) Coomassie 
brilliant blue stain of 3H-leucine CA CIE pattern, using 20% 
reference antibody in the second dimension gel, (B) Autoradiography 
of same plate, (C) Coomassie brilliant blue stain of 3H-leucine . 
CA (bottom well) co-electrophoresed with unlabelled €A (top 
well), using 15% reference antibody in the second dimension 
gel, (D) Autoradiography of same plate. 

Figure 3. 3H-glucosamine CA (crude antigen) CIE patterns. (A) Coomassie 
brilliant blue stain of 3H-glucosamine CA CIE pattern, using 
20% reference antibody in the second dimension gel, (B) Autoradiography 
of same plate, (C) Coomassie brilliant blue stain of 3H-glucosamine 
CA (bottom well) co-electrophoresed with unlabelled CA (top 
well), using 15% reference antibody in the second dimension 
gel, (D) Autoradiography of same plate. 















Despite attempts to standardize experimental procedures, the number 
and pattern of CIE precipitates varied from batch to batch of prepared antigen. 
In this study, variability may have been due to the condition of cell cultures, 
inapparent differences in extraction procedures, concentration of reference 
antibody in the second dimension gel, differences in migration distances 
and diffusion in co-electrophoresis, and slight voltage fluctuations during 
electrophoresis. Batch variation in antigen concentration was the major 
problem, and this may reflect the difficulty in standardizing cell cultures. 
A change in concentration will increase or decrease peak height, causing 
it to become obscured among other peaks, or the antigen concentration may 
be too low to be detected by CBB or autoradiography. Thus, antigen peaks 
detected in the CIE _pattern of one batch may be missing or obscured in the 
pattern of another batch •. Results were more uniform when unlabelled CA 
and labelled CA were co-electrophoresed. 
The 16 virus-specific antigens were identified from separate patterns . . 
and were never found to constitute a single, complete pattern in either a 
CBB stain or autoradiogram. The FBS peak was identified as a fetal bovine 
serum component, which was present in virus inocula. Glycoprotein antigens 
4,6,7 ,9,10 and 11 were found most consistently, while antigens l ,2,3,3a,5,8,l2,13, 
14 and X appeared sporadically. It is possible that Ag 3a may be identicai 
to Ag 2 or Ag 3. This study did not determine whether some antigen peaks 
were degradation products of others. 
26 
Herpes envelope proteins, specifically glycoproteins, are the major 
targets of neutralizing antibodies and play an important protective role in , 
the infected host (1,6,9,12,15,16,29). Additional studies are needed to determine 
which of these PRV antigens are structural or nonstructural, and which of 
the structural antigens are responsible for protection. 
27 
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SUMMARY 
Pseudorabies (Aujeszky's disease) virus infected cell antigens were 
solubilized with Triton X-100. The crude antigen extract was separated 
by concanavalin A, affinity chromatography into bound and unbound fractions. 
The antigen'ic compositions of crude antigen, bound and unbound fractions 
were analyzed.by fused rocket immunoelectrophoresis and cro'ssed immuno-
electrophoresis. The preparations were then mixed with adjuvant and inoculated 
into mice. Mice vaccinated with crude antigen and the bound fraction (containing 
viral glycoprotein antigens 4 and the 5, 6, 7, 8 complex) developed high serum 
neutralizing antibody titers and a high degree of protection against lethal 
challenge with virule.nt pseudorabies virus. Mice vaccinated with the unbound 
fraction (containing viral glycoprotein antigens 9 and 10) developed low serum 
neutralizing antibody titers and a low degree of protection. We conclude 
that concanavalin A bound pseudorabies virus glycoproteins are important 
in establishing humeral and protective immunity in infected mice. 
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INTRODUCTION 
Herpesvirus glycoproteins are considered the major targets of neutralizing 
antibodies and 'play an important, protective role in the infected host (2,lt,5,6,8,9,l I, 
12, 15, 19,20). 
Purification of glycopeptides from turkey herpesvirus infected cell 
extracts has been accomplished with affinity chromatography, followed by 
sodium dodecylsulphate-polyacrylamide gel electrophoresis (SOS-PAGE) 
(19). The glycopeptides were inoculated into chickens and gave partial protection 
against challenge with virulent Marek's disease virus. Incomplete protection 
may have been a result of the SDS treatment, which denatures protein antigens 
with subsequent reduction in immunologic function (3,10,18,19). 
Membrane bound glycoproteins may be extracted efficiently from virus 
infected cells with the nonionic detergent, Triton X-100 (18). The resulting 
extract can be separated by affinity chromatography, yielding immunologically 
active glycoprotein antigens in the bound fraction (3,17). The aim of the 
present study was to isolate pseudorabies virus glycoprotein antigens in this 
manner· and evaluate their role in humoral and protective immunity in mice. 
r 
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MATERIALS AND METHODS 
Virus Propagation 
Plaque-purified pseudorabies virus (PRV) strain S62/26 (13) was obtained 
from D. L. Rock (Veterinary Medical Research Institute, Iowa State University, 
Ames, Iowa). Stock virus was propagated in low passage bovine Jung (BL) 
cell cultures that were grown in 850 cm2 roller bottles. The culture medium 
consisted of Eagle's minimum essential medium with Earle's salts (MEM) 
supplemented with 10% fetal bovine serum, 0.1 % Jactalbumin hydrolysate, 
. 0.16% sodium bicarbonate, 8.3 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic 
acid (HEPES) and antibiotics (JOO I.U. penicillin, 100 ug streptomycin sulfate, 
100 ug kanamycin sulfate and 50 ug gentamicin sulfate per ml). 
Reference Antibody 
Goat anti-PR V serum was provided by \V. A. Hagemoser (Department 
of Veterinary Pathology, Iowa State University, Ames, Iowa). The immunizing 
procedures and preparation of reference antibody were as described previously 
(7). 
Antigen Preparation 
Crude antigen (approximate protein content of 5 mg/ml) was prepared 
by so!ubilizing PRV infected cells in 1 % Triton X-100 as reported previously 
(7). Crude antigen control was prepared from uninfected cells in an identical 
manner. For affinity chromatography, .a JOO ml bed volume of concanavalin 
A (con A) Sepharose (Pharmacia Fine Chemicals, Piscataway, New Jersey) 
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was equilibrated in 0.025 M Tris-Tricine buffer (Biorad Laboratories, Richmond, 
California) containing 1 % (v/v) Triton x~100 '(Sigma Chemical Company, 
St. Louis, Missouri) (TTT buffer, pH 8.6). Twenty mls of crude antigen were 
allowed to adsorb into the column for 30 minutes. The unbound fraction 
was eluted with 200 mls of buffer and designated UB. The bound fraction" 
was eluted with 200 mis of o<-methyl-D-mannoside (Sigma) (25 mg/ml) and 
designated B. Both Band UB fractions were concentrated by ultrafiltration 
(10,000 MW) to 20 mls and dialyzed for 3 days (6 buffer changes) against. 
TTT buffer (pH 8.6). Fractions designated B control and- UB control were 
prepared in an identical manner starting with 20 mls of crude antigen control. 
Preparations were assayed for virus infectivity by inoculating 25 mls of 1:100 
dilutions onto 75 cm2 flask, BL cell monolayers. Cultures were incubated 
at 37°C for 1 hour. Inocula were then removed, replaced with maintenance 
. media and cells were observed for cytopathic effects for a minimum of 2 
weeks. Radiolabelled crude antigen was prepared as described previously 
(7) by the addition of 3H-glucosamine to infected cells 3 hours after adsorption 
with virus. The labelling period lasted 21 hours. 
Immuni;;:ation and Bleeding Schedules 
-
Five-week old, female Swiss Webster mice (Biolab Corporation, St. 
Paul, Minnesota) were acclimatized for Li weeks prior to use in experiments. 
Three 9-week old mice were sacrificed to obtain preinoculation sera. Six 
antigen preparations, crude antigen, crude antigen control, B, B control, 
UB and UB control, were emulsified with equal amounts of Freund's incomplete 
adjuvant and were used to immunize 9-week old mice. A total of two-hundred 
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nineteen mice were inoculated subcutaneously with 0.2 ml doses of emulsified 
antigens. Groups of 40 mice were inoculated with B, UB or crude antigen 
preparations. Groups of 33 mice were inoculated with B control, UB control 
or crude antigen control •. Thirty-three mice served as uninoculated controls. 
At 21 days post-inoculation (PI), all control vaccinates and 33 mice from 
each group of 40 inoculated with viral antigen preparations received a second, 
identical vaccination. Twenty-one mice (groups of 3 mice that were inoculated 
with B, UB or crude antigen preparations) were sacrificed for serum and · 
33. mice remained unvaccinated. At 42 days PI, 42 mice (groups of 7 mice 
that were uninoculated or twice~inoculated with control or viral antigen 
preparations) were sacrificed for serum. 
Challenge Procedures 
Fifteen-week old (the age of experimental animals at challenge) mice 
were used to determine the 50% lethal dose (LD50J endpoint, which was 
calculated by the Reed Muench method (14) to be 104·4 per 0.1 ml of stock 
PR V. At 42 days PI, 156 .vaccinated (control or viral antigen vaccinates) 
and 33 unvaccinated mice were challenged intravenously (tail vein) with 
a 10, 100 or 1000 LD50 dose contained in 0.1 ml serum-free MEM. Mice 
were observed for clinical signs and death for a 2 week period. 
Immunoelectrophoresis 
Crude antigen peaks present in the fused rocket immunoelectrophoresis 
pattern were tentatively identified by comparison of relative peak heights, 
intensity of staining and fusion with individual crude·antigen CIE reference 
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peaks. The antigenic compositions of inocula were then evaluated by comparison 
of their CIE and fused rocket patterns with those of the crude antigen. Crossed 
immunoelectrophoresis of antigen preparations was performed as described 
previously (7) using 15% reference antibody in the second dimension gel. 
Fused rocket immunoelectrophoresis was performed according to Svendsen 
(16). Fifteen-ul samples of antigen preparations were allowed to diffuse 
for I hour in non-antibody containing gel, before electrophoresis into a gel 
containing 15% reference antibody. Intermediate gel CIE, performed according 
to Axelson (!), was used to characterize the reaction of mouse PI antisera 
to precipitating antige_ns in the crude antigen preparation. Fifteen-ul samples 
of crude antigen and 3H-glucosamine labelled crude antigen were co-e!ectrophoresed. 
Serum samples from vaccinates inoculated with the same antigen preparation 
were pooled and incorporated at 20%, into intermediate gels placed between 
the first and second dimension gels. The second dimension gel contained 
15% reference antibody. Reactions of intermediate gel-incorporated, mouse 
antisera with individual antigens were quantitated by measuring the area 
under each antigen peak. The borderline between the first dimensional gel 
and the intermediate gel was used as a baseline. Antigen peak areas from 
test plates were then compared with corresponding antigen areas from a 
simultaneously run control plate. A minimum of 10% decrease in area from 
that of the control plate-arbitrarily was considered to indicate a specific 
reaction of a given antigen with the intermediate gel antisera. Precipitates, 
were visualized by Coomassie brilliant blue R250 stain (CBB) (Biorad) and 
autoradiography. For autoradiography, Ultrofilm 3H (LKB, Rockville, Maryland) 
was placed on the gel side of dried, stained plates and the film was developed 
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after 30 days exposure. 
Serum Neutralization Test 
The plaque-reduction serum neutralization (SN) test was used to determine 
mouse anti-PR V serum titers. One-tenth ml volumes of serum dilutions 
were mixed with an equal amount of MEM containing approximately 150 
plaque forming units of PRY. The virus/serum mixtures were incubated 
for 1 hour at 37°c, and 0.1 ml of these mixtures were inoculated onto monolayers 
of BL cells in 16 mm, 24 well plastic tissue culture plates. Cultures were 
adsorbed for 1 hour and overlain with 1% agarose containing MEM, 1% diethyl-
aminoethane dextran (DEAE), 2% fetal bovine serum, and antibiotics. Cultures 
were incubated at 37°C for 24 hours before fixing and staining. Serum ·neutralization 
titers were expressed as the reciprocal of the highest serum dilution reducing 
the plaque count by at least 50%. 
Statistical Analyses 
A split-plot experimental design was used, where the challenge doses were 
the whole-plot treatments and vaccinations were the split-plot treatments. The 
whole-plot units were cages containing 4 mice each and mice within a cage were 
given different vaccination treatments (B, UB, crude antigen and no vaccination). 
Analysis of variance was used to analyze SN antibody titers and challenge data. 
For purposes of statistical analyses, effects due to vaccination with crude antigen 
were considered to represent the combined effects due to vaccination with Band 
UB. The four vaccination treatments formed a 2 by 2 factorial arrangement based 




Attempts to isolate virus from inocula were unsuccessful. 
Antigens present in inocula are shown in Figure 1. Precipitating antigens 
in the CIE pattern were numbered according to an earlier study, in which 
the FBS peak was found to be a fetal bovine serum component (7). Crude 
antigen peaks in the fused rocket pattern were tentatively identified by 
comparison of relative peak heights, intensity of staining and fusion with 
individual crude antigen CIE reference peaks (not shown). Antigens present 
in fused rocket patterns of individual inocula were identified by fusion with 
peaks in the crude antigen pattern. The crude antigen preparation contained 
the viral antigens 1, 3, 4, the 5, 6, 7, 8 complex, 9, 10, the 11/lla complex 
12, 13, Y and Z. The B preparation (consisting of antigens that were bound 
to the affinity column) contained the viral antigens 4, the 5, 6, 7, 8 complex, 
the 11/lla complex, Y and Z. The UB preparation (consisting of antigens 
that were not bound to the affinity column) contained antigens 9 and 10 
and the 11/ !la complex. Antigens 3, Y and Z were detected only in fused 
rocket immunoelectrophoresis patterns. With the exception of antigens 
Y and Z, the identities of antigens present in fused rocket patterns of B 
and UB preparations were confirmed by CIE (not shown). 
Serologic Response 
Figure 2 gives the standard intermediate gel CIE reference pattern 
for evaluating reactions of antigens with intermediate gel-incorporated mouse 
antisera. The intermediate gel contained mouse preinoculation serum. To 
Figure 1. 
\ 
Identification of antigens present in inocula. Fused rocket 
immunoelectrophoresis was performed on crude antigen (1), 
crude antigen control (2), B (3), B control (4), UB (5), and UB. 
control (6) preparations. (A) Coomassie brilliant blue stain 
of standard crude antigen CIE pattern, (a,c,) Fused rocket 
im munoelectr'ophoresis of viral antigens using crude antigen 
as a reference pattern, (D) Fused rocket immunoelectrophoresis 
of control antigens using crude antigen as a reference pattern. 

Figure 2. Intermediate gel CIE reference pattern for evaluating reactions 
of antigens with intermediate gel-incorporated mouse antisera. 
(A) Coomassie brilliant blue pattern with intermediate gel 
containing 20% preinoculation serum, (B) Autoradiogram of 
the same plate. 
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reduce day to day variation in peak areas, reactions ·with mouse. antisera 
were evaluated also by comparison with simultaneously run controls (not 
shown). Incorporation of the intermediate gel revealed an additional antigen 
(Ag), lla, which was not observed in Figure 1. This antigen comigrated with 
Ag 11 but was not glucosamine labelled. Antigen 11 a was not detected easily 
in CBB patterns. Because CBB patterns in Figure 1 did not have corresponding 
autoradiograms to distinguish Ag 11 from Ag l la,, the peak corresponding 
to one or both of these antigens was designated the 11/ lla complex. With 
the exception of Ag l la, all antigens detected in the intermediate gel CBB 
pattern could be detected also in the corresponding autoradiogram. Antigens 
3, 12, 13, and Y could not be identified positively by intermediate gel CIE. 
Antigen Z was visible more clearly in intermediate gel CIE than it was by 
conventional CIE. 
A summary of intermediate gel C!E serologic data is given in Table 
1. Precipitating antigens are characterized by glucosamine incorporation 
and their reaction with mouse antisera incorporated into intermediate gels. 
Results from the incorporation of 21-day PI mouse antisera into CIE 
intermediate gels are shown in Figure 3. Viral reference peak areas were 
not affected by mouse antisera produced against either B or UB preparations. 
Twenty-one day PI antisera to crude antigen reacted with viral glycoprotein 
an~igens ti, the 5, 6, 7, 8 complex, 9, 10, 11 and X; the nonglycoprotein Ag 
lla also was depressed (not shown). 
Resu.lts from the incorporation of 112-day PI mouse antisera into CIE 
intermediate gels are shown in Figure I/. The antisera produced against the 
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b(+) indicates antigen reaction with anti-UB, anti-B or anti-crude antigen 
antisera incorporated into CIE intermediate gels, (-) indicates no reaction. 
Figure 3. Incorporation of 21-day PI mouse antisera into CIE intermediate 
gels. Autoradiogram patterns were formed by co-electrophoresis 
of unlabelled crude antigen (top wells) with 3tt-glucosamine 
labelled crude antigen (bottom wells). Intermediate gels contained 




Figure q, Incorporation of q2-day PI mouse antisera into CIE intermediate 
gels. Autoradiogram patterns were formed as in Figure 3. 
Intermediate gels contained mouse antisera produced against 
(A) UB, (B) B, and (C) crude antigen preparations. 
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UB preparation reacted with the glycoprotein antigens 9, 10 and 11, and 
the nonglycoprotein Ag l la (not shown), but did not react with Ag 4 or the 
5, 6, 7, 8 complex. The 42-day PI mouse anti-B sera reacted with the glycoprotein 
Ags 4, the 5, 6, 7, 8 complex, 9, 10, 11 and X, and the nonglycoprotein Ag 
lla (not shown). The 42-day PI antisera produced against crude antigen 
reacted with all antigens. The crude antigen control, B control, UB control 
and unvaccinated control antisera had no effect on peak areas (not shown). 
The statistical analysis and factorial arrangement of mouse 21-day 
PI serum neutralizing antibody response data are given in Table 2. The average 
difference between B-present and B-absent was to increase dilutions by 4.8. 
This effect was statistically significant (p = 0.0001). The average difference 
between UB-present and UB-absent showed a dilution increase of 0.2, which 
was not significant. The effect on antibody response with and without B 
was 24 times the effect with and without :UB. Interaction (synergism) between 
B and UB was not significant. 
The statistical analysis and factorial arrangement of mouse 42-day 
PI serum neutralizing antibody response data are given in Table 3. The average 
difference between B-present and B-absent was to increase dilutions by 3.8. 
This effect was statistically significant (p = 0.0001). The average difference 
between UB-present and UB-absent showed a dilution increase of 1.3, which 
also was statistically significant (p = 0.025), but considerably less so than 
with B. The effect on dilutions with and without B was 2.9 times the effect 
with and without UB. Interaction between B and UB was not significant. 
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Table 2. Statistical analysis and factorial arrangementa of mouse 21-day 
PI serum neutralizing antibody response based on the presence or absence 













B-means difference (B) 
0.2 
5.0 
aValues given under B-absent/VB absent, B absent/VB present, B present/VB 
absent and B present/VB present represent antibody responses for unvaccinated 
animals, VB, Band crude antigen vaccinates, respectively. 
b Antibody response is expressed as the average number of two-fold dilutions 
of 21-day mouse Pl antisera required to reach the serum neutralizing endpoint. 
Values are rounded to the nearest tenth and are based on a total of 7 mice. 
cStatistically significant at p = 0.0001. 
d Means of average values (VB-means and B-means) are rounded to the nearest 
tenth. 
eNot statistically significant. 
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Table 3. Statistical analysis and factorial arrangementa of mouse 42-day PI 
serum neutralizing antibody response based on the presence or absence of B 
or VB antigens in the inoculum 
Mean 
VB-absent VB-present B-means difference (B) 
B-absent ob 0.8 0.4 
3.8c 
B-present 6.0 7.7 4.2 
VB-means 4.3 
Mean difference (VB) 
aValues given under B-absent/VB absent, B-absent/VB present, B present/VB 
absent and B present/VB present represent antibody responses for unvaccinated 
animals, VB, Band crude antigen vaccinates, respectively. 
b Antibody response is expressed as the average number of two-fold dilutions 
of 42-day mouse PI antisera required to reach the serum neutralizing 
endpoint. Average values are rounded to the nearest tenth and are based 
on a total of 6 mice. 
cStatistically signifcant at p = 0.0001. 
dMeans of average values (VB-means and B-means) are rounded to the 
nearest tenth. 
eStatistically signifcant at p = 0.025. 
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Combined antibody response data are given in Figure 5. The highest 
antibody responses were found at 42 days PI, in mice inoculated with B and 
crude antigen preparations. The geometric mean titers of 42-day PI antisera 
produced against UB, Band crude antigen preparations were l."(, ,64 and .· 
208, corresponding to 0.8, 6.0 and 7 .7 average two-fold dilutions, respectively. 
Statis.tical analyses of the serologic data {Table 3) indicated that high SN 
response was due to vaccination with .B-containing inocula {con A isolated 
or crude antigen inocula). Vaccinated and unvaccinated control sera gave 
no SN antibody response. 
Protection 
Percent survival data and statistical analyses are given in Table 4. 
Twenty-two percent (2 of 9) of the mice vaccinated with crude antigen control 
survived at the lowest challenge dose. All other controls did not survive. 
At all challenge doses, crude antigen induced the highest percent survival 
followed by B and then UB. For all inocula, survival of vaccinates decreased 
as challenge dose increased. Percent survival data for unvaccinated controls 
and the UB, Band crude antigen vaccinates averaged over all challenge doses 
{lo, 100 and 1000 LD50) are given in Table,5. The average difference between 
B-present and B-absent was to increase percent survival by 35.5. This effect 
was statistically significant {p = 0.000 !). The average difference between 
VB-present and UB-absent showed a percent survival increase of 20.5. This · 
effect was also statistically significant, (p = 0.0049), although considerably 
less so than with B. The effect on percent survival with and without B was 
approximately 1.7 times the effect with and without UB. Interaction between 
Figure 5. Serum neutralizing antibody response at O, 21 and 42 days PI. 
Response was expressed as the average number of two-fold 
dilutions required to reach the serum neutralizing endpoint. 
The preinoculation value (0-day PI) is a mean based on a total 
of 3 mice, 21-day PI values are means based on a total of 7 
mice, and 42 day PI values are means based on a total of 6 
mice. Serum neutralizing response results are given for unvaccinated 
controls (• •) and UP.. (o--o), B (c:r-o), and crude antigen 
(..._,_.)vaccinates. Minimum and maximum SN values (I) 

































































aControl mice were vaccinated with UB control, B control or crude 






Percent survival values at all challenge doses are rounded to the nearest 
whole number and are based on a total of 9 mice. 
cTreated mice were vaccinated with UB, B or crude antigen preparations. 
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Table 5. Statistical analysis and factorial arrangementa of percent survival 
of vaccinates and controls averaged over all challenge doses (10, JOO and 1000 LD50J based on the presence or absence of B or UB antigens in the inoculum · 
Mean 
UB-absent UB-present B-means difference (B) 
B-absent ob 22.0 11.0 
35.5c 
B-present 37.0 56.0 46.5 
.UB-means 39.0 
Mean difference(UB) 
aValues given under B-absent/UB absent, B-absent/UB present, B present/UB 
absent and .B present/UB present represent antibody responses for unvaccinated 
animals, UB, Band crude antigen vaccinates, respectively. 
bPercent survival values are rounded to the nearest whole number 
and are based on a total of 27 mice. 
cStatistically significant at p = 0.0001. 
dMeans of percent survival values (UB-means and B-means). 
eStatistically significant at p = 0.0049. 
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B and UB was not significant. There was some interaction between challenge 
dose and vaccination with B-containing preparations (B and crude antigen) 
(p = 0.038). This interaction was caused by the greater protective effect 
induced by the B-containing inocula at the lowest challenge level than at 
both higher levels. 
Relationship Between Serologic Response and Protection 
The neutralizing antibody response as it relates to protective activity 
of antigens is shown in Figure 6. The data indicated that at all challenge 
doses, higher neutralizing antibody titers and vaccination with B-containing 
preparations were associated with a higher percent survival, while lower 
neutralizing antibody titers and vaccination with the UB preparation were 
associated with a lower percent survival. 
Figure 6. Relationship between neutralizing antibodies and protective activity. 
Percent survival values are based on a total of 9 mice. Mean 
dilution values are based on a total of 6 mice bled at 42 days 
PI. Results are given for unvaccinated controls (l!>), UB (&), 
B (0), and crude antigen (e) vaccinates, at JO LD50 (-), 









































































































































The reaction of antigens with intermediate gel antisera caused a decrease 
in affected peak areas (compared to controls), often accompanied by a generalized 
blurring of the precipitate pattern. In some instances, blurring made identification 
of affected peaks difficult. It is not known whether blurring was a property 
of affected peaks only, or if non-reacting antigen peak.s appeared blurred 
because of the incomplete formation of a higher, affected peak. For the 
purposes of this study, only antigens with decreased peak areas were considered 
to have reacted with intermediate gel antisera. 
We detected viral glycosylated Ags I, 4, the 5,6,7 ,8 complex, 9,10, 
11 and Z, and the nonglycosylated Ag lla in the crude antigen reference 
pattern, which was formed by intermediate gel CIE. Of these antigens, Ags 
4, the 5, 6, 7, 8 complex, the 11/ lla complex, and Z were detected in the 
B preparation, while Ags 9, 10 and the II/Ila complex were detected in 
the UB preparation. Antigens I and Z could not be identified consistently 
in intermediate gel CIE patterns. Antigens 12 and 13 probably were not 
easily detected because of the addition of an intermediate gel in the standard 
CIE reference pattern of crude antigen. Increased migration distance and 
diffusion through CIE gels may have reduced antigen concentrations so that 
observable peaks to Ags 3 and Y were n?t formed. 
Antisera produced against B and UB preparations reacted with both 
antigens in the 11/1 la complex. Anti-B sera also reacted with antigens 9 
and l 0, which were not detected in the B preparation. The reaction of antisera 
to antigens not detected in their corresponding inocula may be due to serological 
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cross-reactivity between antigens 11 and lla and between antigens 9, 10 
and Z, indicating degradation or precursor relationships among antigens. 
It is possible that Ag l la is a nonglycosylated precursor to the glycosylated 
Ag 11; antigens 9, 10 and Z also may represent partially and fully glycosylated 
forms of the same antigen. It is also possible that antigens 9, 10, and Ila 
in the B preparation, and antigen 11 in the UB preparation were present 
in concentrations too low to be detected by immunoelectrophoresis, but 
adequate to evoke an immune response. 
Separation of crude antigen by con A chromatography resulted in incomplete 
separation of glycosylated and nonglycosylated antigens. The glycoprotein 
antigens 9, 10, and possibly 11 were eluted with the UB fraction. A glucosamine 
labelled aht!gen that di.d not bind to con A has been reported previously by 
Vestergaard et al. (18). Incomplete recovery of con A separated antigens 
from the affinity column was indicated by fused rocket immunoelectrophoresis, 
which showed that peaks present in both Band UB preparations were lower 
than the corresponding peaks in the crude antigen preparation. 
All control animals died, except for 2 of 9 crude antigen control vaccinates, 
which survived at the lowest challenge dose. Their survival may have been 
the result of misvaccination with crude antigen, injection of an insufficient 
amount of challenge .dose, or nonspecific stimulation of a generalized immune 
response by adjuvant. 
Combined results indicate that the glycoprotein antigens 4 and the 
5, 6, 7, 8 complex were responsible for the higher humor al and protective 
immunity induced in vaccinated mice. Mice vaccinated with these antigens 
· (B and crude antigen vaccinates) demonstrated 89, 28 and 2296 survival with 
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increasing challenge doses, while mice not receiving these antigens (UB vaccinates 
and unvaccinated controls) demonstrated 28, 5.6 and 0% survival. Survival 
results reflected both the quality and quantity of viral antigens present in 
the different inocula. It is likely that the predominance of glycoprotein 
antigens, the greater antigen mass and the greater number of different antigens 
present in B-containing inoclila all contributed to the higher percent survival 
of B and crude antigen vaccinates. Vaccination with glycoprotein antigens 
9 and IO may have been responsible for the low humeral response and the 
slight protective immunity induced in some UB vaccinates. This would support 
results from previous studies, which indicate the importance of herpesvirus 
glycoproteins in both humoral and protective immunity (4,6,9,12). 
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SUMMARY AND CONCLUSIONS 
. This study involved the characterization of Triton X-100 solubilized, 
PRV infected cell antigens. The crude antigen extract was analyzed by fused 
rocket immunoelectrophoresis, CIE, and intermediate gel CIE. Coomassie 
brilliant blue and autoradiogram patterns revealed 19 virus-specific antigens, 
of which at least 15 were glycosylated. 
The crude antigen was separated into bound and unbound fractions 
by concanavalin A, affinity chromatography. The antigenic compositions 
of crude antigen, bound and unbound fractions were analyzed by fus.ed rocket 
immunoelectrophoresis and CIE. The preparations were mixed with.adjuvant 
and inoculated into mice. Mice vaccinated with crude antigen and the bound 
fraction (containing viral glycoprotein antigens ti and the 5, 6, 7, 8 complex) 
developed high serum neutralizing antibody titers and a high degree of protection 
against lethal challenge with virulent pseudorabies virus. Mice vaccinated 
with the unbound fraction (containing viral glycoprotein antigens 9 and 10) 
-
developed low serum neutralizing antibody titers and a low degree of protection. 
The following conclusions may be made: 
1. The majority of precipitating antigens in the crude antigen extract 
is glycosylated. 
2. Concanavalin A bound PRV glycoproteins are important in establishing 
humoral and protective immunity in mice. 
Further research is needed in the following areas: 
1. Pseudorabies virus infected cell antigens should be compared to those 
present in the virion to identify structural and nonstructural components. 
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2. The ability of the concanavalin A bound fraction to induce cellular 
immunity should be evaluated. 
3. The protective activity of the concanavalin A bound fraction should 
be verified in swine, cattle, and other domestic animals at risk. A 
pseudorabies vaccine prepared using concanavalin A Sepharose could 
be valuable in eradication. Immunoprecipitation methods detected 
antigens~. the 5,6,7 ,8 complex, the 11/ Ila complex, Y and Zin the 
bound fraction, while antigens 9 and 10 were not detected. Serologic 
tests developed to detect immune sera reactions to antigens 9 and 
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